Category Archives: Portfolio Review

Portfolio Review – Healthcare – Actavis

The Schwab Profile – Actavis (ACT) (price of stock is $296.54 as of 6/9/15) is a global, integrated specialty pharmaceutical company. The Company focuses on developing, manufacturing and distributing generic, brand and biosimilar products. The Company produces and markets generic, branded generic, branded and over-the-counter